Rain Oncology, a leading biopharmaceutical company, has unveiled the highly anticipated topline results from the Phase 3 MANTRA trial evaluating Milademetan, a novel treatment for Dedifferentiated Liposarcoma (DDLPS). The trial demonstrated remarkable efficacy, with Milademetan significantly prolonging progression-free survival and exhibiting a favorable safety profile. DDLPS patients who received Milademetan experienced a substantial reduction in disease progression or death, highlighting its potential as a groundbreaking therapeutic option. These promising findings pave the way for Milademetan’s potential approval and subsequent availability as a life-changing treatment for DDLPS, addressing an unmet medical need in the field of oncology.

Read more: https://www.globenewswire.com/news-release/2023/05/22/2673294/0/en/Rain-Oncology-Announces-Topline-Results-from-Phase-3-MANTRA-Trial-of-Milademetan-for-the-Treatment-of-Dedifferentiated-Liposarcoma.html